Perseus Proteomics (TYO:4882) and UBE have entered a collaborative research agreement focused on antibody-drug conjugates (ADC), which are used to kill cancer cells, according to its filing on Monday.
The partnership will enhance the development of PPMX-T004, an ADC, and explore additional ADCs using external drug discovery sources.
Their combined technologies will optimize antibody and drug/linker combinations for effective treatments.
Price (JPY): $610.00, Change: $+2.0, Percent Change: +0.33%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。